Abrocitinib is a Janus kinase 1 (JAK1) inhibitor for atopic dermatitis. It helps reduce inflammation by targeting specific immune pathways, leading to symptom relief. Abrocitinib is an orally available, small molecule inhibitor of Janus kinase 1 (JAK1) that is used to treat moderate-to-severe atopic dermatitis. It is grouped under the following drug class(es): JAK inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Cibinqo, N-[cis-3-[Methyl(7H-pyrrolo[2 and 3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide. Its PubChem CID is 78323835.
Abrocitinib
| CAS No | 1622902-68-4 |
|---|---|
| Molecular Formula | C14H21N5O2S |
| Molecular Weight | 323.42 g/mol |
| Synonyms | N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor for atopic dermatitis. It helps reduce inflammation by targeting specific immune pathways, leading to symptom relief.
The listed CAS number is 1622902-68-4.
The listed molecular formula is C14H21N5O2S.
The listed molecular weight is 323.42 g/mol.
N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide.
The source lists Cibinqo, N-[cis-3-[Methyl(7H-pyrrolo[2 and 3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide.